<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291783</url>
  </required_header>
  <id_info>
    <org_study_id>9936-101</org_study_id>
    <secondary_id>2013-002307-34</secondary_id>
    <nct_id>NCT02291783</nct_id>
  </id_info>
  <brief_title>Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics in young and elderly healthy volunteers of HTL9936, a selective M1 receptor
      agonist intended for the treatment of cognitive disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics in young and elderly healthy volunteers of HTL9936, a selective M1 receptor
      agonist intended for the treatment of cognitive disorders. This study is a single ascending
      dose study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events, as a measure of safety and tolerability</measure>
    <time_frame>From signing of informed consent up to 30 days after the final visit</time_frame>
    <description>AE reports include a description of the AE, date and time of onset and resolution, intensity, and relationship to IMP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Safety Lab parameters as a measure of safety and tolerability</measure>
    <time_frame>Screening, Day-1, at select dosing days, and at 5 to 7 days post dose for single doseand 15 to 17 days post first dose in multiple dosing.</time_frame>
    <description>Hematology, clinical chemistry, urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital signs as a measure of safety and tolerability</measure>
    <time_frame>Screening, Day-1, at select dosing days and at 5 to 7 days post dose for single dose, and 15 to 17 days post first dose in multiple dosing.</time_frame>
    <description>Pulse rate,body temperature,blood pressure, and orthostatic changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-lead electrocardiograms as a measure of safety and tolerability</measure>
    <time_frame>Screening, pre-dose, at select dosing days and at 5 to 7 days post dose for single dose,and 15 to 17 days post first dose in multiple dosing.</time_frame>
    <description>Change in ECG parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures in plasma as measured by Peak plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose, multiple time points to 24h, at select dosing days, and 5 to 7 days post dosefor single dose,and 15 to 17 days post first dose in multiple dosing.</time_frame>
    <description>Peak plasma concentration (Cmax), time at occurrence of Cmax (tmax), Area under the plasma concentration versus time curve (AUC) 0-t, 0- infinity, percent of AUC 0-infinity, Cmax normalized by dose, AUC 0-t normalized for dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures in cerebro spinal fluid (CSF) in young males as measured by max observed CSF (Cmax CSF)</measure>
    <time_frame>Part 1 - 1h, 2h,3h post dose</time_frame>
    <description>Maximum observed CSF concentration (Cmax CSF), area under the CSF concentration versus time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures to assess the food effect as measured by ANOVA</measure>
    <time_frame>Pre-dose, multiple time points to 24h, and at 12h, 24h and 5 to 7 days post dose.</time_frame>
    <description>Food effect analysis will be based on analysis of variance (ANOVA) for treatment differences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response as measured by pupillometry</measure>
    <time_frame>Multiple time points Day1 to 6h post dose Part 1 only.</time_frame>
    <description>Changes in average pupil diameter as measured in 3 different conditions of lux.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures in urine in young males and elderly male and female subjects as measured by amount of urine excreted at collection intervals</measure>
    <time_frame>Pre-dose,multiple 4h collection intervals to 24h post dose on select dosing days to Day 10 for multiple dosing.</time_frame>
    <description>Amount excreted in urine at each collection interval (Ae1-t2) all parts. Cumulative amount excreted to 12h and 24h (Ae0-t) depending on Part. Cumulative urine excreted of unchanged drug to 24h (Fe%) and to 12h depending on Part. Volume of urine collected during each collection interval (Vur), and renal clearance (CLr) all parts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response as measured by Bond and Lader visual analogue scale</measure>
    <time_frame>Day 1 at multiple timepoints to 24h post dose.</time_frame>
    <description>Changes in 3 factor scores (Alertness, Contentedness and Calmness) which will be derived from the individual VAS scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response as measured by changes in qEEG and Event Related Potentials (ERP)</measure>
    <time_frame>Screening, Day-1, Day 4, Day 9 multiple dosing regimen only</time_frame>
    <description>qEEg and ERP (P50 sensory gating, Mismatch Negativity and P300)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>HTL0009936</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTL0009936 single and multiple ascending oral doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTL0009936 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HTL0009936 matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0009936</intervention_name>
    <description>Single dose</description>
    <arm_group_label>HTL0009936</arm_group_label>
    <other_name>9936, HTL0009936</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0009936 placebo</intervention_name>
    <description>Placebo single dose</description>
    <arm_group_label>HTL0009936 Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index of ≥19 and ≤ 30kg/m²

          -  Healthy subject free from any clinically significant illness or disease

          -  Female subjects must be ≥65 years

        Exclusion Criteria:

          -  Subject who is predicted to be a CYP2D6 poor or ultra rapid metabolizer

          -  History of hypersensitivity to study drug

          -  History of epilepsy or seizures

          -  Subject with previous history of suicidal behavior

          -  Subjects with significant hearing impairment

          -  Subjects with an abnormal EEG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelize Koch, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Early Phase Clinical Unit</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

